A National Leader
The University of Maryland Department of Radiation Oncology is a national leader in translational research in radiation therapy.
The department is one of the top 10 radiation oncology departments in the country for amount of federal funding received for cutting-edge research. As of 2024, the Department of Radiation Oncology ranks in the top 10 nationally and internationally for National Cancer Institute (NCI)-sponsored national clinical trials cooperative group accruals. In 2023, the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) ranked third in the United States as a top accruing main member for NRG Oncology trials.
This strong reputation in research has led UMGCCC to be one of only four cancer centers in the country to have a Master Research Agreement with Varian Medical Systems, the market leader in the development of medical technology.
The GammaPod System, Invented in the Department of Radiation Oncology
Mission
Our research department’s mission is to facilitate and provide services to:
- UM faculty researchers, assisting with study start-up and administration.
- Patients and the general public, providing up-to-date information about ongoing clinical studies in the University of Maryland Department of Radiation Oncology.
- Sponsors, helping to identify University of Maryland investigators for research participation.
Divisions within Research
Learn more about our:
Highly focused radiation treatment SABR offers hope for patients with advanced prostate cancer
More information about open radiation oncology clinical trials:
Radiation Oncology Clinical Trials